Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas
- PMID: 33247679
- PMCID: PMC8033136
- DOI: 10.31557/APJCP.2020.21.11.3229
Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas
Abstract
Background: IDH1 mutation shows diagnostic, prognostic, and predictive value in gliomas. Direct Sanger sequencing is considered the gold standard to detect IDH1 mutation. However, this technology is not available in most neuropathological centers in developing countries such as Indonesia. Immunohistochemistry (IHC) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) have also been used to detect IDH1 mutation. This study aimed to compare DNA sequencing, IHC, and PCR-RFLP in detecting IDH1 mutations in gliomas.
Methods: Research subjects were recruited from Dr. Sardjito Hospital. Genomic DNA was extracted from fresh or formalin-fixed paraffin-embedded samples of tumor tissue. DNA sequencing, PCR-RFLP and IHC were performed to detect IDH1 mutation. Sensitivity, specificity, and accuracy of PCR-RFLP and IHC were calculated by comparing them to DNA sequencing as the gold standard.
Results: Among 61 recruited patients, 13 (21.3%) of them carried a mutation in codon 132 of the IDH1 gene, as shown by DNA sequencing. PCR-RFLP and DNA sequencing have a concordance value of 100%. Meanwhile, the concordance value between IDH1 R132H IHC and DNA sequencing was 96.7%. The sensitivity, specificity, positive predictive values, negative predictive values, and accuracy for PCR-RFLP were all 100%. On the other hand, the sensitivity, specificity, and accuracy of IHC were 92.3%, 97.9%, and 96.7%, respectively.
Conclusion: This study showed that both PCR-RFLP and IHC have high accuracy in detecting IDH1 mutation. We recommend a combination of PCR-RFLP and IHC to detect IDH1 mutation in resource-limited settings.<br />.
Keywords: DNA Sequencing; Glioma; IDH1 gene; PCR–RFLP; immunuhistochemistry.
Figures



Similar articles
-
A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.Acta Neuropathol Commun. 2014 Jun 2;2:58. doi: 10.1186/2051-5960-2-58. Acta Neuropathol Commun. 2014. PMID: 24889502 Free PMC article.
-
Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.Neuro Oncol. 2013 Jun;15(6):718-26. doi: 10.1093/neuonc/not015. Epub 2013 Mar 13. Neuro Oncol. 2013. PMID: 23486690 Free PMC article.
-
Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.Mol Med Rep. 2015 Sep;12(3):4376-4381. doi: 10.3892/mmr.2015.3987. Epub 2015 Jun 23. Mol Med Rep. 2015. PMID: 26130305
-
TERT Immunohistochemistry as a Surrogate Marker for TERT Promoter Mutations in Infiltrating Gliomas.Appl Immunohistochem Mol Morphol. 2023 May-Jun 01;31(5):288-294. doi: 10.1097/PAI.0000000000001118. Epub 2023 Mar 24. Appl Immunohistochem Mol Morphol. 2023. PMID: 36952585 Free PMC article. Review.
-
New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status.Brain Tumor Pathol. 2011 Jul;28(3):203-8. doi: 10.1007/s10014-011-0050-4. Epub 2011 Jul 7. Brain Tumor Pathol. 2011. PMID: 21735252 Review.
Cited by
-
Clinical Evaluation of IDH Mutation Status in Formalin-Fixed Paraffin-Embedded Tissue in Gliomas.Mol Diagn Ther. 2023 May;27(3):371-381. doi: 10.1007/s40291-022-00638-7. Epub 2023 Jan 23. Mol Diagn Ther. 2023. PMID: 36690887 Free PMC article.
-
Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma.J Cancer Res Clin Oncol. 2023 Jul;149(8):4253-4267. doi: 10.1007/s00432-022-04336-z. Epub 2022 Sep 5. J Cancer Res Clin Oncol. 2023. PMID: 36063222 Free PMC article.
-
Predicting IDH Mutation in Glioma Patients Using Deep Learning Algorithms with Conformal Prediction.J Imaging Inform Med. 2025 Jun 25. doi: 10.1007/s10278-025-01580-w. Online ahead of print. J Imaging Inform Med. 2025. PMID: 40563037
References
-
- Arita H, Narita Y, Matsushita Y, et al. Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol. 2014;32:22–30. - PubMed
-
- Bujko M, Kober P, Matyja E, et al. Prognostic value of IDH1 mutations identified with PCR–RFLP assay in glioblastoma patients. Mol Diagn Ther. 2010;14:163–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous